Results 81 to 90 of about 2,842 (113)

Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland. [PDF]

Eur J Clin Microbiol Infect Dis, 2023
Nordmann P, Bouvier M, Poirel L.
europepmc   +1 more source

Effectiveness and safety of meropenem-vaborbactam versus ceftazidime-avibactam in multidrug-resistant Gram-negative infections: a systematic review and meta-analysis with trial sequential analysis. [PDF]

Antimicrob Agents Chemother
Mohammad S, Al Namer Y, Rahimeh W, Albalas M, Almangour TA.   +4 more
europepmc   +1 more source

Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion. [PDF]

Antibiotics (Basel), 2023
Marino A, Campanella E, Stracquadanio S, Calvo M, Migliorisi G, Nicolosi A, Cosentino F, Marletta S, Spampinato S, Prestifilippo P, Stefani S, Cacopardo B, Nunnari G.   +12 more
europepmc   +1 more source

Genotypic Evolution of Klebsiella pneumoniae Sequence Type 512 during Ceftazidime/Avibactam, Meropenem/Vaborbactam, and Cefiderocol Treatment, Italy. [PDF]

Emerg Infect Dis, 2023
Arcari G, Cecilia F, Oliva A, Polani R, Raponi G, Sacco F, De Francesco A, Pugliese F, Carattoli A.   +8 more
europepmc   +1 more source

Meropenem/vaborbactam activity against carbapenem-resistant Klebsiella pneumoniae from catheter-related bloodstream infections. [PDF]

Front Cell Infect Microbiol
Sivori F, Francalancia M, Truglio M, Cavallo I, Pronesti C, Fabrizio G, Celesti I, Cazzani A, Furzi L, Pimpinelli F, Di Domenico EG.   +10 more
europepmc   +1 more source

Meropenem-Vaborbactam for Treatment of Carbapenem-Resistant Enterobacterales: A Narrative Review of Clinical Practice Evidence. [PDF]

Infect Dis Ther
Bassetti M, Giacobbe DR, Vena A, Poulakou G, Rossolini GM, Soriano A, Nicolau DP.   +6 more
europepmc   +1 more source

Pathogen-Specific Clinical Trials: A New Paradigm in Clinical Trials for Multidrug-Resistant Organisms

Infectious Diseases and Therapy, 2018
Sarah C. J. Jorgensen, Michael J. Rybak
doaj   +1 more source

Head-to-head: meropenem/vaborbactam versus ceftazidime/avibactam in ICUs patients with KPC-producing K. pneumoniae infections- results from a retrospective multicentre study. [PDF]

Infection
Marino A, Maraolo AE, Mazzitelli M, Oliva A, Geremia N, De Vito A, Gullotta C, Scaglione V, Vania E, Lo Menzo S, Navalesi P, Volpicelli L, Fiori A, Prestifilippo P, Cattelan A, Mastroianni CM, Madeddu G, Cacopardo B, Nunnari G.   +18 more
europepmc   +1 more source

Population pharmacokinetics of meropenem-vaborbactam in acutely ill hospitalized patients with various degrees of renal dysfunction including continuous renal replacement therapy. [PDF]

Antimicrob Agents Chemother
Reed G, Valadez A, Smith BJ, McCreary EK, Kline EG, Neely MN, Squires KM, Shields RK, Rhodes NJ.   +8 more
europepmc   +1 more source

A molecular analysis of meropenem-vaborbactam non-susceptible KPC-producing Klebsiella pneumoniae. [PDF]

Antimicrob Agents Chemother
Yasmin M, Marshall SH, Chen L, Rhoads DD, Jacobs MR, Rojas LJ, Perez F, Hujer AM, Hujer KM, van Duin D, Fowler V, Chambers HF, Kreiswirth BN, Bonomo RA, Antibacterial Resistance Leadership Group.   +14 more
europepmc   +1 more source